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Supplementary Figure 1.  Sleep traits are phenotypically and genetically correlated 
in men and women.    Phenotypic correlation between the reported sleep traits, using 
Spearman correlation are shown stratified by sex (a. men, b. women).  Color scale 
represents the strength of the correlation.  Genetic correlation between the reported sleep 
traits shown stratified by sex, as measured by LDSC (c. men, d. women).  Color scale 
represents the strength of the correlation.  Blue indicates positive correlation, red 
indicates negative correlation.   
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Supplementary Figure 2.  Manhattan and Q-Q plots for genome-wide association 
analysis of sleep duration, insomnia symptoms, and excessive daytime sleepiness.  
GWAS results for sleep duration (a-b), insomnia symptoms (c-d), and excessive daytime 
sleepiness (e-f).  Manhattan plots a, c, and e show the –log10 p-values (y-axis) for all 
genotyped and imputed SNPs passing quality control in each GWAS, plotted by 
chromosome (x-axis).  Red line is genome-wide significant (5x10-8) and blue line is 1×10-
6.  Q-Q plots b, d, and f show the expected verses observed  p-values from our association 
analysis.  Heritability estimates were calculated using BOLT-REML and lambda inflation 
values using GenABEL in R.  
  
   
  
 
  
 Supplementary Figure 3.  Regional association plots for genome-wide significant 
and suggestive loci.  Panel a-d sleep duration, e-g insomnia symptoms, h-n excessive 
daytime sleepiness, o excessive daytime sleepiness adjusted for depression, p  
excessive daytime sleepiness adjusted for BMI, q-t sex specific loci for insomnia 
symptoms.  Chromosomal position is indicated on the x-axis and –log10 p-values for each 
SNP (filled circles and squares) is indicated on the y-axis, with the lead SNP shown in 
purple (400kb window around lead SNP shown).  Genes within the region are shown in 
the lower panel.  The blue line indicates the recombination rate.  Additional SNPs in the 
locus are colored according to linkage disequilibrium (r2) with the lead SNP (estimated by 
LocusZoom based on the CEU HapMap haplotypes).  Squares represent genotyped 
SNPs and circles represent imputed SNPs. 
 
  
Supplementary Figure 4.  Manhattan and QQ plot for sex stratified genome-wide 
association analysis of sleep duration (a-d), sleep disruption (e-h), and daytime 
sleepiness (i-l).  Manhattan plots a,c,e,g,i, and k show the –log10 p-values (y-axis) for all 
genotyped and imputed SNPs passing quality control in each GWAS, plotted by 
chromosome (x-axis).  Red line is genome-wide significant (5x10^-8) and blue line is 
1×10^-6.  Plots b,d,f,h,j, and l show the expected verses observed P values from our 
association analysis.  Heritability estimates were calculated using BOLT-REML and 
lambda inflation values using GenABEL in R.  
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A. Sleep Duration: chr2: rs62158211 (PAX-8 region) 
 
B. Sleep Duration: chr2: rs1380703 (VRK2 region) 
 
C. Sleep Duration: chr7: rs10953765 (FOXP2 region) 
 
D. Sleep Duration: chr10: rs146977851 (PCDH15 region) 
 
E. Sleep Duration: chr 14: rs61980273 (PRIMA1 region) 
 
F. Insomnia Symptoms: chr 2: (MEIS1 region; variants with r2>0.6 shown) 
 
G. Insomnia Symptoms: chr 17: rs145258459 (TMEM132E region) 
 
 
H. Insomnia Symptoms: chr X: rs5922858 (CYCL1 region) 
 
I. Insomnia Symptoms: chr 5: rs3792900 (TGFBI region: females only)  
 
J. Insomnia Symptoms: chr 5: rs13192566 (WDR27 region: males only)  
 
K. Daytime Sleepiness: chr 1: rs192315283 (HSD52 region) 
 
L. Daytime Sleepiness: chr 2: rs76645968 (ASB3 region)  
 M. Daytime Sleepiness: chr 3: rs920065 (MRPS35P1/ MRPS36P1 region)  
 
N. Daytime Sleepiness: chr 4: rs115320831 (TMEM144 region)    
 
O. Daytime Sleepiness: chr 5: rs35309287 (DPYSL3 region)    
 
P. Daytime Sleepiness: chr 6: rs189689339 (FAM46A region)  
 
Q. Daytime Sleepiness: chr 15: rs17507216 (CPEB1 region)   
 
 
R. Daytime Sleepiness: chr X: rs73536079 (AR, OPHN1 region)  
 
S. Daytime Sleepiness: chr 3: rs182765975 (ROBO1 region) 
 
T. Daytime Sleepiness: chr 12: rs142261172 (TMEM132B region)    
 
U. Multi-sleep Trait: chr 1: rs12140153 (INADL region)  
 
V. Multi-sleep Trait: chr 6: rs3122163 (HCRTR2 region)  
 
 
Supplementary Figure 5.  Functional annotations of associated variants from 
Haploreg 4.1. Annotations of lead SNPs and correlated variants (r2>0.8 to lead SNP 
except as indicated) are derived based on documentation available at 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php and include human 
genome hg38 positions, LD (r2 and D’) to lead SNP shown in red in the 1KG EUR 
population, allele frequency in 1KG continental populations, conserved regions by GERP 
and Siphy annotation, tissue-specific chromatin state methylation marks (promoter, 
enhancer marks) based on the core-HMM 15 state model, tissue-specific DNAse1 
hypersensitivity sites, bound proteins from Chip-seq experiments (ENCODE), predicted 
effect of regulatory SNP on transcription factor binding using position-weighted matrices, 
GWAS catalog hits (accessed October 31, 2015 by Haploreg 4.1), and GRASP build 2.0.0 
QTLs complemented by 10 other eQTL studies including gTEX v6 and GEUVADIS 
analysis, as well as gene annotation by RefSeq and dbSNP annotation of variant function.  
  
  
 
  
  
Supplementary Figure 6.  Association of core circadian clock gene regions with sleep 
traits. Regional association plots for core circadian clock genes (BMAL1 (a-c), BMAL2 (d-f), 
CRY1 (g-i), CRY2 (j-l), CLOCK (m-o), PER1 (p-r), PER2 (s-u), PER3 (v-x)) across sleep traits.  
Genes within the region are shown in the lower panel.  The blue line indicates the recombination 
rate.  Filled circles show the -log10 p-value for each SNP, with the lead SNP shown in purple.  
Additional SNPs in the locus are colored according to correlation (r2) with the lead SNP (estimated 
by LocusZoom based on the CEU HapMap haplotypes). 
  
 
Supplementary Figure 7.  Manhattan and Q-Q plot for genome-wide association 
multi-trait analysis of sleep duration, insomnia symptoms, excessive daytime 
sleepiness, and chronotype.  Plot A shows the genome-wide association signals 
associated with the composite sleep phenotype.  The Manhattan plot shows the –log10 p-
values (y-axis) for all genotyped and imputed SNPs passing quality control in each 
GWAS, plotted by chromosome (x-axis).  Red line is genome-wide significant (5x10-8) 
and blue line is 1×10-6.  Q-Q plot (B) shows the expected verses observed P values from 
our association analysis.  Signals are annotated with nearest gene symbol.  Plot B shows 
the expected verses observed p-values from the multi-trait association analysis.  
Heritability estimates were calculated using BOLT-REML and lambda inflation values 
were calculated using GenABEL in R.  
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Supplementary Figure 8. MEIS1 region association with insomnia symptoms. 
Regional association plot with lead association signal represented by SNP rs113851554 
(punadj=10-19; plot A). Conditioning on the lead SNP abolishes the lead regional association 
signal and shows no strong secondary association signals (best SNP rs62143994, p=10-
4; plot B).  Analysis conditional on previously reported RLS GWAS SNP rs2300478 
(punadj=0.01; plot C) does not alter insomnia symptoms association signals.  Analysis 
conditional on rs11693221, a rare MEIS1 3’ UTR SNP discovered by sequence analysis 
and also associated with RLS, abolishes the lead association signal (punadj=10-14; plot D).  
Chromosomal position is indicated on the x-axis and –log10 p-values for each SNP (filled 
circles) is indicated on the y-axis, with the lead SNP shown in purple (200kb window 
around lead SNP shown).  Genes within the region are shown in the lower panel.  The 
blue line indicates the recombination rate.  Additional SNPs in the locus are colored 
according to linkage disequilibrium (r2) with the lead SNP (estimated by LocusZoom 
based on the CEU HapMap haplotypes).  
Characteristic
r p -val r p -val r p -val
Sex (M) 52,817 (47%) 59,868 (53%) 112,586 -0.01 0.002 -0.14 <0.001 0.04 <0.001
Age, y 58.12 (7.96) 57.3 (7.83) 57.69 (7.90) 0.06 <0.001 0.09 <0.001 0.13 <0.001
Sleep duration, hrs 7.19 (1.07) 7.19 (1.09) 7.19 (1.08) - - -0.25 <0.001 -0.03 <0.001
Insomnia Symptoms -0.25 <0.001 - - 0.08 <0.001
       Never/Rarely 16,009 (55.8%) 10,964 (36.0%) 26,973 (46%)
       Usually 12,674 (44.2.0%) 19,481 (64.0%) 32,155 (54%)
Excessive Daytime Sleepiness -0.03 <0.001 0.08 <0.001 - -
       Never/Rarely 39,613 (75.0%) 46,762 (78.1%) 86,375 (76.7%)
       Sometimes 11,496 (21.8%) 11,365 (19.0%) 22,861 (20.3%)
       Often 1,524 (2.9%) 1,446 (2.4%) 2,970 (2.6%)
       All of the time 5 (0%) 3 (0%) 8 (0%)
Depression (n=96,409) 1,913 (3.6%) 2,829 (4.7%) 4,242 (4.4%) -0.07 <0.001 0.18 <0.001 0.11 <0.001
Psychiatric Medication (n=112,867) 503 (1%) 1,190 (2.0%) 1,693 (1.5%) 0.02 <0.001 0.03 <0.001 0.01 <0.001
Self-reported Sleep Apnea (n=99,500) 301 (0.6%) 97 (0.2%) 398 (0.4%) -0.01 0.058 0.01 0.013 0.03 <0.001
BMI, kg/m2 (n=75,640) 29.66 (1.26) 27.66 (1.22) 29.23 (6.82) -0.01 0.016 0.02 <0.001 0.07 <0.001
Townsend Deprivation Index (SES) (n=112,376) -1.51 (3.02) -1.55 (2.92) -1.53 (2.97) -0.04 <0.001 0.05 <0.001 0.05 <0.001
Smoking Status (n=112,225) -0.02 <0.001 0.05 <0.001 0.02 <0.001
       Never 26,236 (49.6%) 34,489 (57.9%) 60,625 (54.0%)
       Former 19,834 (37.7%) 18,704 (31.4%) 38,538 (34.3%)
       Current 6,670 (12.7%) 6,392 (10.7%) 13,062 (11.6%)
Employment Status, retired (n=102,416) 18,754 (38.6%) 22,799 (42.3%) 41,553 (40.6%) 0.13 <0.001 0.10 <0.001 0.13 <0.001
Marital Status, spouse/partner (n=103,565) 40,899 (82.2%) 42,027 (78.1%) 82,926 (80.0%) 0.05 <0.001 -0.05 <0.001 -0.03 <0.001
Snoring (n=104,945) 24,119 (48.3%) 15,790 (28.7%) 39,909 (38.0%) -0.02 <0.001 0.04 <0.001 -0.09 <0.001
Supplementary Table 1.  Descriptive Characteristics of UKBiobank subjects of European ancestry used for GWAS (N=112,586).
Self-reported measures of sleep duration, insomnia symptoms, and excessive daytime sleepiness, as well as covariates.Our sample size for each phenotype-specific GWAS is 
a subset of the 112,586.  The smaller sample size for each GWAS is attributable to subjects with either missing, “prefer not to answer”, or “don’t know” responses.  Phenotype 
correlation was calculated using the Spearman correlation.  
Sleep Duration
Insomnia 
Symptoms
Excessive 
Daytime 
Sleepiness     
Pair-wise Phenotype Correlation
Mean (SD)                                                                                    
N cases (%)
Males Females All
  
Supplementary Table 2.  Genome-wide significant results from sex stratified analyses for sleep traits in the UK Biobank.
Trait SNP 
Chr:position 
NCBI 37
Nearest 
Gene(s) 
Alleles 
(E/A) 
EAF 
Imputation 
Quality
n OR [95% CI] p-val n OR [95% CI] p-val
interaction 
p-val
Insomnia 
Symptoms
rs3792900 5:135393754 TGFBI C/T 0.47 0.99 28,511 1.007 [0.974-1.041] 0.70 30,287 1.102 [1.065-1.14] 2.16x10-8 2.55x10-4
rs13192566 6:169961635 WDR27 G/C 0.86 0.99 28,664 1.144 [1.091-1.200] 3.17x10-8 30,420 1.000 [0.957-1.053] 0.8781 8.89x10-5
Males Females
E=effect allele, A=alternative allele, Chr=chromosome, OR=Odds Ratio, CI=confidence interval, imputation quality from Impute2. EAF=effect allele frequency.  Note, increasing odds 
ratio indicates increased insomnia symptoms.  Analyses are adjusted for age, genetic ancestry and genotyping array and performed stratified by sex. Bold denotes genome-wide 
significant signals (p<5x10-8).
  
Supplementary Table 3. Conditional Analysis.  Secondary signal is the lead SNP after conditioning on lead GWAS SNP.
SNP Nearest Gene(s) Chr:position NCBI 37 Secondary SNP Chr:position NCBI 37 Alleles (E/A) Beta (SE) p-val
Sleep Duration
rs62158211 PAX8 2:114106139 rs183854670 2:115284353 G/T -0.75 (0.18) 4.63E-05
rs1380703
LOC647016/ 
LOC100131953 2:57941287 rs375652393 2:58089047 T/C 0.48 (0.13) 2.64E-04
rs10953765 FOXP2 7:114291435 rs144294405 7:114368853 T/TTC -0.10 (0.03) 5.98E-04
rs146977851 PCDH15 10:56570954 rs191835902 10:56511106 A/G 0.59 (0.15) 8.59E-05
rs61980273 PRIMA1 14:94218949 rs184953371 14:94221477 T/C -0.53 (0.11) 2.07E-06
Insomnia Symptoms OR (95%CI)
rs576106307 ARHGEF10L 1:18007282 rs185896278 1:17807007 T/C 3.52 (1.46 - 8.47) 7.33E-05
rs113851554 MEIS1 2:66750564 rs62143994 2:66696080 T/C 0.93 (0.90 - 0.96) 7.10E-05
rs376775068 ADCK5 8:145604659 8:145651625_C_T 8:145651625 T/C 0.33 (0.18 - 0.61) 1.04E-05
rs145258459 TMEM132E 17:32986155 rs546643659 17:32812400 A/G 1.35 (1.09 - 1.65) 6.87E-04
rs531814036 ACBD4 17:43219921 rs186141052 17:43101593 C/T 0.50 (0.21 - 1.21) 6.01E-04
rs182765975 ROBO1 3:78538431 rs557285265 3:78706604 A/G 0.55 (0.35 - 0.85) 1.47E-04
rs142261172 TMEM132B 12:126049981 rs540711617 12:126033341 T/A 1.29 (1.06 - 1.58) 1.14E-04
rs5922858 CYCL1 X:82971008 rs147330274 X:82957216 C/T 1.14 (1.04 - 1.25) 4.67E-03
Daytime Sleepiness
rs192315283 HSD52 1:59531543 rs371398972 1:59677576 C/A 0.76(0.16) 2.40E-06
rs76645968 ASB3 2:53827686 rs570953237 2:54059985 T/C 0.60 (0.14) 1.10E-05
rs920065
MRPS35P1/ 
MRPS36P1 3:5893776 rs148404446 3:6138051 T/A 0.31 (0.08) 1.37E-04
rs115320831 TMEM144 4:159178375 rs7663422 4:159185860 A/C 0.39 (0.12) 7.74E-04
rs35309287 DPYSL3 5:146775386 5:146997228_C_T 5:146997228 T/C 1.00 (0.27) 2.51E-04
rs189689339 FAM46A 6:82375372 rs562379407 6:82303450 G/A 0.82 (0.21) 9.16E-05
rs17507216 CPEB1 15:83226925 rs189218438 15:83362909 A/C 0.13 (0.04) 4.82E-04
rs73536079 AR/OPHN1 X:67154206 rs4827412 X:67288207 A/G 0.01 (0.01) 2.13E-02
Conditional association results include a ±500kb window around the lead SNP.  Chr=chromosome, E=effect allele, A=alternate allele, SE=standard error, OR=Odds ratio, 
95%CI= 95% confidence interval.
 SNP CHR POS
Alleles 
(E/A)
INFO MAF N
Aditional adjustment 
beyond baseline
Beta (SE) P
Sleep Duration
rs10953765 7 114,291,435 A/G 0.977 0.446 74,025 - -0.02 (0.006) 9.34x10
-5
74,025 Sleep Apnea -0.02 (0.006) 9.30x10
-5
74,025 BMI -0.02 (0.006) 1.01x10
-4
71,091 Depression -0.02 (0.006) 9.86x10
-5
74,025 Psychiatric Medication -0.02 (0.006) 9.52x10
-5
73,931 SES -0.02 (0.006) 1.41x10
-4
73,840 Smoking -0.02 (0.006) 1.43x10
-4
73,476 Employment Status -0.02 (0.006) 7.71x10
-5
68,261 Marital Status -0.02 (0.006) 4.63x10
-5
69,190 Snoring -0.02 (0.006) 6.76x10
-5
rs1380703 2 57,941,287 G/A 0.893 0.382 59,469 - -0.02 (0.006) 7.63x10
-4
59,469 Sleep Apnea -0.02 (0.006) 7.65x10
-4
59,469 BMI -0.02 (0.006) 7.51x10
-4
57,073 Depression -0.02 (0.007) 1.39x10
-3
59,469 Psychiatric Medication -0.02 (0.006) 8.13x10
-4
59,395 SES -0.02 (0.006) 8.00x10
-4
59,309 Smoking -0.02 (0.006) 6.07x10
-4
59,021 Employment Status -0.02 (0.006) 1.06x10
-3
54,837 Marital Status -0.02 (0.007) 1.16x10
-3
55,524 Snoring -0.03 (0.007) 1.23x10
-4
rs146977851 10 56,570,954 T/C 0.965 0.029 74,893 - -0.05 (0.017) 4.85x10
-3
74,893 Sleep Apnea -0.05 (0.017) 4.85x10
-3
74,893 BMI -0.05 (0.017) 4.80x10
-3
71,922 Depression -0.05 (0.017) 4.53x10
-3
74,893 Psychiatric Medication -0.05 (0.017) 5.39x10
-3
74,798 SES -0.05 (0.017) 3.96x10
-3
74,710 Smoking -0.05 (0.017) 6.39x10
-3
74,337 Employment Status -0.05 (0.017) 2.72x10
-3
69,082 Marital Status -0.05 (0.018) 5.00x10
-3
70,000 Snoring -0.05 (0.018) 9.95x10
-3
rs61980273 14 94,218,949 A/G 1.000 0.039 75,476 - 0.06 (0.014) 9.85x10
-6
75,476 Sleep Apnea 0.06 (0.014) 1.00x10
-5
75,476 BMI 0.06 (0.014) 9.96x10
-6
72,481 Depression 0.06 (0.014) 4.03x10
-5
75,476 Psychiatric Medication 0.06 (0.014) 1.01x10
-5
75,381 SES 0.06 (0.014) 1.05x10
-5
75,291 Smoking 0.06 (0.014) 1.37x10
-5
74,917 Employment Status 0.06 (0.014) 2.86x10
-5
69,617 Marital Status 0.07 (0.015) 3.94x10
-6
70,549 Snoring 0.06 (0.015) 4.91x10
-5
rs62158211 2 114,106,139 T/G 0.992 0.214 74,729 - 0.04 (0.007) 2.89x10
-10
74,729 Sleep Apnea 0.04 (0.007) 2.91x10
-10
74,729 BMI 0.04 (0.007) 2.73x10
-10
71,761 Depression 0.04 (0.007) 1.65x10
-10
74,729 Psychiatric Medication 0.04 (0.007) 2.66x10
-10
74,635 SES 0.04 (0.007) 4.06x10
-10
74,548 Smoking 0.04 (0.007) 3.70x10
-10
74,179 Employment Status 0.04 (0.007) 2.07x10
-10
68,927 Marital Status 0.04 (0.007) 4.03x10
-10
69,852 Snoring 0.04 (0.007) 1.15x10
-9
Insomnia Symptoms OR [95%CI] P
rs113851554 2 66,750,564 T/G 1.000 0.056 39,812 - 1.27 [1.19-1.35] 1.39x10
-13
39,812 Sleep Apnea 1.27 [1.19-1.35] 1.47x10
-13
39,812 BMI 1.27 [1.19-1.35] 1.50x10
-13
38,278 Depression 1.29 [1.21-1.38] 4.73x10
-14
39,812 Psychiatric Medication 1.27 [1.19-1.35] 1.55x10
-13
39,759 SES 1.27 [1.20-1.36] 8.49x10
-14
39,704 Smoking 1.27 [1.19-1.35] 1.87x10
-13
39,527 Employment Status 1.27 [1.19-1.35] 1.88x10
-13
36,595 Marital Status 1.26 [1.18-1.35] 7.14x10
-12
37,180 Snoring 1.27 [1.19-1.36] 6.33x10
-13
Supplementary Table 4.  Sensitivity analyses adjusting for factors known to associate with sleep duration, insomnia symptoms, or excessive daytime sleepiness.
 rs145258459 17 32,986,155 T/C 0.695 0.017 38,305 - 0.71 [0.60-0.82] 1.17x10
-5
38,305 Sleep Apnea 0.70 [0.60-0.82] 1.13x10
-5
38,305 BMI 0.70 [0.60-0.82] 1.08x10
-5
36,825 Depression 0.72 [0.62-0.85] 1.20x10
-4
38,305 Psychiatric Medication 0.70 [0.60-0.82] 9.58x10
-6
38,254 SES 0.70 [0.60-0.82] 9.43x10
-6
38,202 Smoking 0.71 [0.60-0.83] 1.54x10
-5
38,030 Employment Status 0.70 [0.60-0.82] 8.94x10
-6
35,200 Marital Status 0.69 [0.59-0.81] 8.74x10
-6
35,764 Snoring 0.74 [0.63-0.87] 3.01x10
-4
rs376775068 8 145,604,659 C/G 0.672 0.066 32,923 - 0.85 [0.77-0.92] 2.05x10
-4
32,923 Sleep Apnea 0.85 [0.77-0.92] 2.27x10
-4
32,923 BMI 0.85 [0.78-0.93] 2.61x10
-4
31,660 Depression 0.84 [0.77-0.92] 2.75x10
-4
32,923 Psychiatric Medication 0.85 [0.77-0.92] 2.23x10
-4
32,880 SES 0.85 [0.78-0.93] 4.01x10
-4
32,824 Smoking 0.85 [0.78-0.93] 2.77x10
-4
32,684 Employment Status 0.85 [0.78-0.93] 2.92x10
-4
30,256 Marital Status 0.85 [0.78-0.93] 6.22x10
-4
30,751 Snoring 0.85 [0.77-0.93] 3.83x10
-4
rs531814036 17 43,219,921 C/CT 0.911 0.420 32,086 - 1.08 [1.04-1.11] 6.86x10
-6
32,086 Sleep Apnea 1.08 [1.04-1.11] 6.51x10
-6
32,086 BMI 1.08 [1.04-1.11] 8.42x10
-6
30,839 Depression 1.08 [1.04-1.12] 2.47x10
-5
32,086 Psychiatric Medication 1.08 [1.04-1.11] 7.58x10
-6
32,043 SES 1.08 [1.04-1.12] 5.43x10
-6
32,002 Smoking 1.08 [1.04-1.11] 1.81x10
-5
31,868 Employment Status 1.08 [1.04-1.11] 8.59x10
-6
29,491 Marital Status 1.08 [1.04-1.12] 2.08x10
-5
29,976 Snoring 1.07 [1.03-1.11] 1.08x10
-4
rs576106307 1 18,007,282 CT/C 0.893 0.212 33,570 - 0.91 [0.87-0.95] 2.30x10
-6
33,570 Sleep Apnea 0.91 [0.87-0.95] 2.35x10
-6
33,570 BMI 0.91 [0.87-0.95] 2.89x10
-6
32,266 Depression 0.92 [0.88-0.96] 4.72x10
-5
33,570 Psychiatric Medication 0.91 [0.87-0.95] 2.37x10
-6
33,526 SES 0.91 [0.88-0.95] 8.30x10
-6
33,477 Smoking 0.91 [0.87-0.95] 3.40x10
-6
33,330 Employment Status 0.91 [0.87-0.95] 4.06x10
-6
30,887 Marital Status 0.92 [0.87-0.96] 6.37x10
-6
31,325 Snoring 0.91 [0.87-0.95] 3.37x10
-6
rs5922858 X 82,971,008 G/T 0.992 0.849 39,512 - 0.88 [0.84-0.92] 1.29x10
-7
39,512 Sleep Apnea 0.88 [0.84-0.92] 1.34x10
-7
39,512 BMI 0.88 [0.84-0.92] 1.17x10
-7
37,990 Depression 0.88 [0.84-0.92] 1.84x10
-7
39,512 Psychiatric Medication 0.88 [0.84-0.92] 1.07x10
-7
39,459 SES 0.88 [0.84-0.92] 1.84x10
-7
39,406 Smoking 0.88 [0.84-0.93] 1.88x10
-7
39,233 Employment Status 0.88 [0.84-0.92] 4.70x10
-8
36,325 Marital Status 0.88 [0.84-0.93] 5.46x10
-7
36,899 Snoring 0.87 [0.83-0.92] 4.57x10
-8
Excessive Daytime Sleepiness Beta (SE) P
rs115320831 4 159,178,375 A/G 0.981 0.298 73,280 - -0.01 (0.003) 1.96x10
-5
73,280 Sleep Apnea -0.01 (0.003) 2.41x10
-5
73,280 BMI -0.01 (0.003) 1.90x10
-5
70,364 Depression -0.01 (0.003) 3.39x10
-5
73,280 Psychiatric Medication -0.01 (0.003) 2.13x10
-5
73,186 SES -0.01 (0.003) 2.88x10
-5
73,102 Smoking -0.01 (0.003) 2.54x10
-5
72,739 Employment Status -0.01 (0.003) 1.01x10
-5
67,586 Marital Status -0.01 (0.003) 3.07x10
-5
68,526 Snoring -0.01 (0.003) 5.24x10
-5
 rs17507216 15 83,226,925 A/G 1.000 0.232 75,639 - 0.01 (0.003) 4.87x10
-6
75,639 Sleep Apnea 0.01 (0.003) 4.58x10
-6
75,639 BMI 0.01 (0.003) 4.00x10
-6
72,624 Depression 0.01 (0.003) 5.38x10
-5
75,639 Psychiatric Medication 0.01 (0.003) 5.27x10
-6
75,544 SES 0.01 (0.003) 3.68x10
-6
75,451 Smoking 0.01 (0.003) 4.08x10
-6
75,079 Employment Status 0.01 (0.003) 1.54x10
-6
69,749 Marital Status 0.02 (0.003) 1.86x10
-6
70,711 Snoring 0.02 (0.003) 1.56x10
-6
rs189689339 6 82,375,372 T/C 0.664 0.004 74,733 - 0.06 (0.032) 4.71x10
-2
74,733 Sleep Apnea 0.06 (0.032) 4.80x10
-2
74,733 BMI 0.06 (0.032) 4.36x10
-2
71,756 Depression 0.06 (0.033) 8.69x10
-2
74,733 Psychiatric Medication 0.06 (0.032) 4.59x10
-2
74,640 SES 0.07 (0.032) 3.28x10
-2
74,549 Smoking 0.06 (0.032) 4.68x10
-2
74,180 Employment Status 0.07 (0.032) 4.21x10
-2
68,927 Marital Status 0.06 (0.033) 5.33x10
-2
69,864 Snoring 0.07 (0.033) 3.26x10
-2
rs192315283 1 59,531,543 C/T 0.757 0.010 74,322 - 0.06 (0.016) 7.77x10
-5
74,322 Sleep Apnea 0.07 (0.016) 6.10x10
-5
74,322 BMI 0.07 (0.016) 6.24x10
-5
71,360 Depression 0.07 (0.017) 2.65x10
-5
74,322 Psychiatric Medication 0.07 (0.016) 7.04x10
-5
74,229 SES 0.06 (0.016) 9.01x10
-5
74,140 Smoking 0.07 (0.016) 5.17x10
-5
73,775 Employment Status 0.07 (0.016) 5.10x10
-5
68,530 Marital Status 0.06 (0.017) 1.53x10
-4
69,478 Snoring 0.05 (0.017) 2.14x10
-3
rs35309287 5 146,775,386 T/TA 0.937 0.030 74,463 - -0.03 (0.008) 8.14x10
-5
74,463 Sleep Apnea -0.03 (0.008) 7.20x10
-5
74,463 BMI -0.03 (0.008) 8.03x10
-5
71,491 Depression -0.03 (0.008) 2.89x10
-4
74,463 Psychiatric Medication -0.03 (0.008) 8.64x10
-5
74,368 SES -0.03 (0.008) 1.31x10
-4
74,277 Smoking -0.03 (0.008) 5.67x10
-5
73,912 Employment Status -0.03 (0.008) 1.35x10
-4
68,658 Marital Status -0.03 (0.008) 9.41x10
-4
69,614 Snoring -0.03 (0.008) 6.32x10
-4
rs76645968 2 53,827,686 C/G 0.990 0.023 75,463 - -0.03 (0.008) 1.87x10
-4
75,463 Sleep Apnea -0.03 (0.008) 2.18x10
-4
75,463 BMI -0.03 (0.008) 1.72x10
-4
72,456 Depression -0.03 (0.008) 2.90x10
-4
75,463 Psychiatric Medication -0.03 (0.008) 1.74x10
-4
75,368 SES -0.03 (0.008) 2.08x10
-4
75,277 Smoking -0.03 (0.008) 1.56x10
-4
74,905 Employment Status -0.03 (0.008) 1.56x10
-4
69,586 Marital Status -0.03 (0.009) 2.63x10
-4
70,550 Snoring -0.03 (0.009) 4.09x10
-4
rs920065 3 5,893,776 C/G 0.957 0.176 71,634 - -0.02 (0.003) 3.47x10
-6
71,634 Sleep Apnea -0.02 (0.003) 3.04x10
-6
71,634 BMI -0.02 (0.003) 2.53x10
-6
68,787 Depression -0.02 (0.003) 5.25x10
-6
71,634 Psychiatric Medication -0.02 (0.003) 3.37x10
-6
71,546 SES -0.02 (0.003) 1.75x10
-6
71,455 Smoking -0.02 (0.003) 3.21x10
-6
71,111 Employment Status -0.02 (0.003) 1.55x10
-6
66,056 Marital Status -0.01 (0.004) 2.46x10
-4
66,941 Snoring -0.02 (0.004) 4.00x10
-6
  
 
  
 
 
 
 
  
rs182765975 3 78,538,431 T/G 0.855 0.003 75,312 - 0.08 (0.022) 3.34x10
-4
75,312 Sleep Apnea 0.08 (0.022) 3.46x10
-4
75,312 BMI 0.08 (0.022) 3.00x10
-4
72,310 Depression 0.08 (0.022) 2.18x10
-4
75,312 Psychiatric Medication 0.08 (0.022) 3.38x10
-4
75,217 SES 0.08 (0.022) 4.79x10
-4
75,124 Smoking 0.08 (0.022) 3.08x10
-4
74,754 Employment Status 0.08 (0.022) 2.13x10
-4
69,453 Marital Status 0.07 (0.023) 1.35x10
-3
70,409 Snoring 0.08 (0.022) 2.85x10
-4
rs142261172 12 126,049,981 A/G 0.915 0.004 75,355 - 0.11 (0.019) 6.05x10
-9
75,355 Sleep Apnea 0.11 (0.019) 7.79x10
-9
75,355 BMI 0.11 (0.019) 7.05x10
-9
72,353 Depression 0.12 (0.019) 1.65x10
-9
75,355 Psychiatric Medication 0.11 (0.019) 6.15x10
-9
75,261 SES 0.11 (0.019) 1.09x10
-8
75,167 Smoking 0.11 (0.019) 3.25x10
-9
74,796 Employment Status 0.11 (0.019) 7.51x10
-9
69,483 Marital Status 0.11 (0.020) 1.13x10
-8
70,449 Snoring 0.11 (0.020) 4.38x10
-8
rs73536079 X 67,154,206 T/G 0.903 0.003 75,583 - 0.74 (0.147) 4.88x10
-7
75,583 Sleep Apnea 0.74 (0.146) 4.71x10
-7
75,583 BMI 0.75 (0.146) 3.34x10
-7
72,572 Depression 0.73 (0.145) 4.51x10
-7
75,583 Psychiatric Medication 0.74 (0.146) 4.67x10
-7
75,488 SES 0.74 (0.146) 3.87x10
-7
75,395 Smoking 0.74 (0.146) 4.62x10
-7
75,026 Employment Status 0.74 (0.146) 4.71x10
-7
69,697 Marital Status 0.75 (0.153) 9.54x10
-7
70,659 Snoring 0.73 (0.145) 4.50x10
-7
Sleep trait GWAS results are adjusted for age, sex, genetic ancestry, and genotyping array as baseline and additional covariates as indicated for each analysis.  
All analyses performed in subjects with non-missing covariates, therefore unadjusted results may differ from table 1.  E=effect allele, A=alternative allele, 
MAF=minor allele frequency, SE=standard error. 
  
SNP 
Chr:position 
NCBI 37
Nearest 
Gene(s) 
Candidate genes In silico functional assessment (Haploreg 4.1)
Sleep duration
rs62158211 2:114106139 PAX8
This lead SNP is in strong LD with the CHARGE multi-ethnic sleep duration signal (rs1823125 
r2=0.95, D'=0.98 in 1KG CEU). The locus contains 6 genes under the peak (IL1RN, PSD4, 
PAX8, PAX8-AS1, IGKV1OR2-108, AC016745.3, CBWD2, FOXD4L1 ).  IL1RN  encodes 
interleukin 1 Receptor antagonist, and is upregulated in sleep-deprived mice. PSD4 , Pleckstrin 
And Sec7 Domain Containing 4, is a guanine exchange factor for the RAS superfamily protein 
Arf6 that helps to assemble and stabilize tight junctions. PAX-8 , paired-box 8 is a thyroid and 
kidney specific nuclear paired box homeodomain transcription factor involved in thyroid 
development.  IGKV1OR2-108  is an immunoglobulin kappa variable gene segment. CBWD2 is a 
family member of the cobalamin synthetase W domain proteins, FOXD4L1 is a neural forkhead 
box transcription factor that expands neural ectoderm by repressing genes that promote onset of 
neural differentiation, and upregulating genes that maintain immature proliferative neural 
precursors. AC016745.3 is a poorly characterized lincRNA with increased expression in recurrent 
glioma. 
This region is adjacent to the head to head fusion site at chr 2q13-q14.1 that 
formed chromosome 2 during human evolution from hominids. Eqtls peaks 
are observed at the lead GWAS SNP for widely expressed gene 
AC016745.3 (thyroid, adrenal gland and skin), widely expressed CBWD2 
(thyroid), IGKV1OR2108 (thyroid and skin) and FOXD4L1 (thyroid; gTEX 
consortium) with lower gene expression for the sleep duration increasing 
allele. Eqtls of lead SNPs for PAX-8 were also reported by the CHARGE 
Consortium. The lead SNPs are also associated with ratios of metabolites 
C3:1/C16-0H acylcarnitine to hydroxyacylcarnitine ratio (p=10-8), C3:1 
involved in energy metabolism, and serum ratio of (linoleamide 
(18:2n6))/(stearidonate (18:4n3)p=1.5x10-6).  
rs1380703 2:57941287 VRK2
This locus is between annotated genes SNORD78 (169kb) and VRK2 (332kb). SNORD78 codes 
for a small nucleolar RNA upregulated in lung and prostate cancer. VRK2 encodes the protein 
vaccinia related kinase 2, a serine/threonine kinase and modulator or ERK/MAPK and CREB-
regulated pathways.Independent variants at the VRK2 locus have previously been associated with 
schizophrena and epilepsy (rs13026414 r2=0.34, D'=0.89; rs11682175 r2=0.40, D'=0.82) and 
conditional analysis suggests that they are not associated with sleep duration. Rare variants have 
been identified in a family with bipolar disorder (PMID: 24348429).Pseudogenes in the locus 
include LOC100131953.
VRK2 is widely expressed, with greatest expression in gTEX in EBV-
tranformed lymphocytes. The lead SNP is common but has no known SNPs 
in LD; the alternate allele is predicted to abolish Tregulatory cell specifying 
FoxP3 binding, enhance binding of the important pluripotency transcription 
factor Nanog and reduce binding of POU2F2 (OCT2) and TATA. No 
enhancer or promoter elements are predicted. 
rs10953765 7:114291435 FOXP2
This locus contains 3 genes, FOXP2 , MIR3666  and MDFIC . FOXP2 encodes the forkhead 
box P2 protein and mutations cause developmental speech and language disorders in 
humans.MIR3666 lies within an intron of FOXP2. MDFIC encodes for the MyoD family inhibitor 
protein that has a cysteine rich C terminal domain important for transcriptional regulation of viral 
gene expression.  Notably, an intronic SNP in MDFIC was associated with clozapine induced cell 
death in lymphoblastoid cell lines (rs2709505 r2=0.009, D'=0.36 to our lead SNP). 
The lead SNP lies within an intron of FOXP2 and alters binding of 
TATA-binding protein, with the sleep duration reducing allele showing 
enhanced binding. Notably, a corelated variant is highly conserved and 
the alternate allele decreases binding of zinc finger protein Zfp128 and 
enhances binding of Zfp161.
rs146977851 10:56570954 PCDH15
There is one gene at the locus, PCDH15  which encodes for protocadherin-related 15, a member 
of the cadherin superfamily involved in generating neural diversity for neuronal differentiation and 
synapse formation. It has previously been linked to hearing loss (Usher syndrome) and may be 
disrupted in neuropsychiatric disorders such as autism and schizophrenia.
The lead SNP alters bindng sites for 12 proteins, with most dramatic 
differential effects by allele for binding of FOXP1, FOXQ1, POU3f2_2 and 
Sox6 transcription factors. 
rs61980273 14:94218949 PRIMA1
This locus contains the genes UNC79 (unc-79 homolog (C. elegans)), PRIMA1 (proline rich 
membrane anchor 1), FAM181A and FAM181A-AS1 and ASB2 (ankyrin repeat and SOCS box 
containing 2) . Unc79 is a calcium channel previously implicated in circadian rhythms and sleep-
wake regulation in Drosophila. PRIMA1 encodes for proline rich membrane anchor 1, organizes 
acetylcholinesterase into tetramers to tether it to neuronal membranes. A previously reported 
SNP in the gene has been implicated in a GWAS study of caffeine related sleep disturbance 
(rs6575353 r2=0.003, D'=1 to our lead SNP; P>10-6) unadjusted for insomnia. 
The SNP lies within PRIMA1 and demonstrates a promoter mark in 
mesenchymal stem cells, enhancer marks in multiple brain regions, muscle 
and instestines, and the alternate allele is predicted to reduce binding of AP-
2, a transcription factor expressed in neural crest celles, and slightly 
enhance binding of BDP1. 
Insomnia Symptoms
rs576106307 1:18007282 ARHGEF10L
ARHGEF10L encodes Rho guanine nucleotide exchange factor 10 like and may be involved in cerebral visual 
impairment. ACTL8 encodes actin-like 8, RCC2 encodes Regulator of chromosome condensation-2 that may 
be involved in directional cell signaling 
This variant is not present in the 1KG reference database.  
rs113851554 2:66750564 MEIS1
ME1S1 is a homeodomain protein important for stem cell self-renewal, and plays important roles 
in the development of the brain and heart. It has a role in motor neuron connectivity in Drosophila, 
retinal and lens development in mouse, and Substance P expression in the amygdala.
This variant is highly conserved, and acts as an enhancer in multiple cell 
lines including hematopoeitic cells, smooth muscle, lung, pancreas and 
liver. The most highly correlated variant is an enhancer in stem cells, fetal 
heart, adrenal gland and the rare allele is predicted to dramatically reduce 
binding of REST. In zebrafish, the enhancer element encompassing this 
variant has an enhancer role. 
rs376775068 8:145604659 ADCK5 ADCK5  encodes AarF Domain Containing Kinase 5 on chr 1q24.3. This variant is not present in the 1KG reference database.  
Supplementary Table 5. Description of candidate genes within association signals and In silico  functional interpretation using variant annotations (Haploreg 4.1)
 rs145258459 17:32986155 TMEM132E
TMEM132 family members are important in neuronal development, this gene has been implicated in 
autosomal-recessive nonsyndromic hearing loss. The gene family has roles in  panic/anxiety disorder, and 
bipolar disorder.
This variant is 20kb downstream of the gene, conserved (GERP), has enhancer marks 
in the brain and GI tissues, has DNA hypersensitivity sites in induced pluripotent 
stem cells, brain and GI.
rs531814036 17:43219921 ACBD4
This region harbors the genes DCAKD, NMT1, PLCD3, ACBD4, HEXIM1, HEXIM2, FMNL1, MAP3K14, MAP3K14-
AS1, SPATA32 . ACBD4 encodes an acyl-CoA binding domain containing protein involved in maintenance of 
Golgi structure and transport. 
This variant is not present in the 1KG reference database.  
Males rs13192566 6:169961635 WDR27
This region comprises the genes THBS2, WDR27, C6orf120, PHF10, TCTE3, ERMARD, LINC00242 and 
LINC00574 . WDR27 encodes a WD repeat containing protein, the family of which can act as a scaffold for 
protein-protein interactions important for cell signaling.  Variants around this gene have been implicated in 
multiple human diseases including type 1 diabetes. 
The lead SNP and correlated variant are in WDR27 and are predicted to alter binding 
sites for multiple transcription factors, but little else is known. 
Females rs3792900 5:135393754 TGFBI
This region harbors the genes SLC25A48 (solute carrier family 25 member 48) , IL9 (interleukin 9), FBXL21 
(F-box and leucine rich repeat protein 21 (gene/pseudogene) , LECT2 (leukocyte cell derived chemotaxin 2), 
TGFBI (transforming growth factor beta induced), VTRNA2-1, SMAD5 (SMAD family member 5), SMAD5-AS1, 
LOC389332, TRPC7 (transient receptor potential cation channel subfamily C member 7).  TGBI encodes the 
TGF-beta induced gene, an extracellular matrix protein responsible for human corneal dystrophy and that 
may act as a tumor suppressor gene.
There are many SNPs in this region that might be causal, with slightly greater 
probability for the lead SNP using PICS. The lead SNP is in an enhancer and binds 
CTCF in many cell types, is an expression-qtl for SMAD5 in monocytes (p=10-9) and 
for SMAD5 (p=10-30) and TGFBI (p=10-6) in whole blood and alters transcription 
factor binding sites for E2A, TBX5 and ZEB1.
Daytime Sleepiness
rs192315283 1:59531543 HSD52
This region contains genes for non-coding RNAs LINC01135, LINC01358, uncharacterized predicted protein 
HSD52, JUN proto-oncogene, AP-1 transcription factor subunit, MYSM1, Myb like, SWIRM and MPN 
domains 1 protein, and FGGY, a carbohydrate kinase domain containing protein, that phosphorylates 
carbohydrates. Variants in FGGY have been irreproducibly associated with ALS. 
The lead SNP is predicted to be the likely causal variant, and is downstream of 
HSD52. It is highly conserved and is within an enhancer element in ES cells, blood 
and GI tissues, altering transcription factor binding sites for Ets.
rs76645968 2:53827686 ASB3
This region harbors genes ASB3, GPR75-ASB3, CHAC2, GPR75, ERLEC1, MIR3682 and PSME4 . ASB3 encodes an 
ankyrin repeat and SOCS box containing protein. The SOCs box may couple suppressor of cytokine signaling 
proteins to elongin complexes for degradation. This region has been previously implicated in responsiveness 
to short-acting beta-2 agonists in asthma and is associated with smooth muscle proliferation. GPR75-ASB3 is 
the product of a read-through transcript and the encoded protein is identical to ASB3 with a novel N-
terminus from GPR75. GPR75 is a G-protein coupled receptor. CHAC2 encodes a cation transport regulator 
homolog and the familymay act as γ-glutamyl cyclotransferases that degrade glutathione. ERLEC1 encodes 
an endoplasmic reticulum lectin that functions in N-glycan recognition, and may function as a regulator of 
protein degradation and multiple cellular stress response pathways. MIR3682 is a microRNA of unknown 
function. PSME4 encodes the proteasome activator subunit 4 involved in DNA repair. 
The lead SNP is within ASB3, and has 25% probability to be the causal SNP based on 
PICS analysis. It is in a region of enhancer histone marks in the brain, gastrointestinal 
tissues and in the pancrease. The SNP is predicted to alter a binding site for 
NRSF/REST, a neuron-restrictive silencing factor important for the establishing of 
neuronal specificity, by being expressed in non-neuronal and neuronal lineages. A 
correlated SNP is a trans-eqtl SNP, associated with gene expression of LRP5L, located 
on chr22, in peripheral blood monocytes. 
rs920065 3:5893776
MRPS35P1/ 
MRPS36P1
MRPS35P1 and MRPS36P1 are mitochondrial ribosomal protein S35 and S36 pseudogenes.
There are two SNPs in strong LD, both lead SNPs alter transcription factor binding 
sites for multiple transcription factors, most predominantly interferon regulatory 
factor for rs920065 and forkhead transcription factor Foxf2 for rs5846411, that is 
expressed predominantly in the lung and placenta.
rs115320831 4:159178375 TMEM144
This region harbors poorly characterized genes FAM198B and transmembrane domain protein TMEM144, as 
well as relaxin/insulin like peptide receptor 1 (RXFP1), a G-protein coupled receptor. RXFP1 has been 
dysregulated in multiple diseases including bipolar disorder, stroke and cancer, is implicated in stress 
response, and also plays critical roles in spermatogenesis, pregnancy and birth as a receptor for relaxin. In 
zebrafish, it plays an important role in neurophysiology during early development
The lead SNP lies 1.8kb 3' of the gene TMEM144, and  is predicted to most strongly 
alter binding of FOXP1 and SIX5 transcription factors. A correlated variant is also 
predicted to alter FOXP1 and Pou3f3 binding. 
rs35309287 5:146775386 DPYSL3
This region contains genes STK32A, DPYSL3, JAKMIP2-AS1, JAKMIP2. DPYSL3 encodes a dihydropyrimidinase 
like protein implicated as a tumor suppressor and ALS gene, and regulates the inflammatory response of 
activated microglia.  STK32A encodes a serine/threonine kinase.  JAKMIP2 is janus kinase and microtubule 
interacting protein 2, component of the Golgi matrix, and may be a scaffold or repress secretory processes. 
Two variants could be causal by PICS credible set analysis, and are 1bp apart, 
suggesting that they might reflect the same insertion-deletion polymorphism. Both 
variants are predicted to lie in an enhancer site active in ES cell derived ectodermal 
cells, fat, ovary, heart and lung and alter binding sites for multiple transcription 
factors, most strongly for PAX-6, lead variant, and GATA for the correlated variant. 
rs189689339 6:82375372 FAM46A
This region contains the Fam46a gene that has been implicated in retinal diseases, is thought to be a poly-A 
polymerase, is enriched in Hcrt cells, with variants associated with posterior cortical atrophy variant of 
Alzheimer's disease. Mutations in mice cause skeletal dysplasia. 
The lead variant is predicted to be causal and significantly alter binding of SREBP1 
and p300. 
  
 
 
 
rs17507216 15:83226925 CPEB1
This region harbors multiple genes including GOLGA6L10  (golgin A6 family-like 10), ADAMTS7P1  (ADAMTS7 
pseudogene 1), UBE2O2P2 , RPS17  (ribosomal protein S17), CPEB1  (cytoplasmic polyadenylation element 
binding protein 1), AP3B2  (adaptor related protein complex 3 beta 2 subunit), SNHG21  (small nucleolar RNA 
host gene 21), SCARNA15 (small Cajal body-specific RNA 15), FSD2 (fibronectin type III and SPRY domain 
containing 2), WHAMM  (WAS protein homolog associated with actin, golgi membranes and microtubules), 
HOMER2  (homer homolog 2 (Drosophila). CPEB1 regulates subcellular trafficking and translation of synaptic 
plasticity-related mRNAs, and may play a role in diurnal trafficking of mRNAs in astrocytes.
There are multiple SNPs that might be causal, and lie in the genes RP11-152F13.10 or 
CPEB1. The lead SNP is predicted to be an enhancer in ES cell derived endoderm and 
brain regions including the angular gyrus and it and associated SNPs form an eqtl 
peak  for multiple genes (most strongly AP3B2, but also genes RP13-608F4.1,RP11-
152F13.10, RP11-152F13.7, AC105339.1 and EFTUD1) in adipose tissue, aorta, 
cerebellum, breast, fibroblasts, colon, esophagus, heart, lung, muscle, skin, stomach, 
thyroid and whole blood. The SNP rs17356118 in strong LD is conserved, predicted to 
be a strong enhancer in multiple tissues and alters the glucocorticoid response 
element. 
adj for 
depressi
on
rs182765975 3:78538431 ROBO1
ROBO1  encodes the roundabout guidance receptor 1 and is a neuronal axon guidance receptor previously 
implicated in dyslexia.
Little functional annotation is available for the three variants predicted to have 
highest probability for causality. While the lead variant is not predicted to alter 
transcription factor binding sites, the other two SNPs may alter multiple transcription 
factor binding sites including most strongly for NKX2.2 and NKX2.3 for variant 
rs191435135.
adj for 
BMI
rs142261172 12:126049981 TMEM132B
TMEM132B  is a TMEM132  family member involved in brain development that is differentially expressed in 
intracranial aneurysm. 
Both correlated SNPs have equal probability of being causal. The lead SNP activates a 
glucocorticoid response element, and has DNAase hypersensitivity sites in the blood, 
while the correlated SNP is predicted to be an enhancer in the brain  and has DNA 
hypersensitivity sites in the brain. 
Multi-sleep trait
rs12140153 1:62352479 INADL
This region harbors TM2D1  (TM2 domain containing 1), L1TD1  (LINE1 type transposase domain 
containing 1), KANK4  (KN motif and ankyrin repeat domains 4), USP1  (ubiquitin specific peptidase 1), 
DOCK7  (dedicator of cytokinesis 7) and INADL. INADL  encodes PATJ, a crumbs cell polarity complex 
component, with multiple PDZ domains. It organizes multimeric complexes at the plamsa membrane and 
localizes to tight junctions. Variants in INADL  have previously been associated with obesity. 
The lead SNP is predicted to be causal and is a conserved missense SNP, that is 
predicted to be probably damaging by Polyphen and deleterious by SIFT. It is 
predicted to be a missense variant in all four transcripts (Transcript 
ENST00000316485 p.G1573V,  ENST00000371158 G1543V,  ENST00000543708  
p.G357V, and ENST00000545929,  p.G188V). Further, it might slightly alter 
transcription-factor binding and have a regulatory role. 
rs3122163 6:55164327 HCRTR2
This region harbors the orexin receptor, HCRTR2 , a G-protein coupled receptor involved in sleep-wake 
regulation and regulation of feeding behavior.
Multiple SNPs in this region may be causal, and while the lead SNP is not well 
annotated, a correlated SNP rs9475186 is predicted to be within a strong bivalent 
promoter and alter transcription factor binding of ETS transcription factor which has 
roles in immune system and cancer.
Trait Disease Gene Set Genes
Fold 
Enrichment
P Adjusted
Sleep Duration Nelson syndrome IL36B,RABL2A,FOXD4L1,PSD4,IL36G,IL36A 12.02 6.04E-05
Communication Disorders FOXP2,PCDH15 23.24 6.80E-03
Williams Syndrome   RABL2A,FOXD4L1,PSD4 8.77 8.70E-03
Insomnia SymptomsVirus Diseases CCL7,NMT1,VPS28,PLCD3,GPT,HEXIM1,CCL8,CCL1 10.88 2.91E-05
Bronchitis CCL13,CCL7,CCDC103,CCL11,CCL8,CCL1 16.8 2.91E-05
Sexually Transmitted Diseases CCL7,NMT1,VPS28,GFAP,PLCD3,HEXIM1,CCL11 12.32 2.91E-05
Brenner tumour of ovary CCL13,CCL7,GFAP,CCL11,CCL8,CCL1 17.93 2.91E-05
Immunologic Deficiency SyndromesCCL7,NMT1,VPS28,GFAP,PLCD3,HEXIM1 15.29 2.00E-04
HIV Infections CCL7,NMT1,VPS28,GFAP,PLCD3,HEXIM1 9.33 2.00E-04
Retroviridae Infections CCL7,NMT1,VPS28,GFAP,PLCD3,HEXIM1 7.65 2.00E-04
HIV CCL7,NMT1,VPS28,GFAP,PLCD3,HEXIM1,CCL8,CCL1 7.03 2.00E-04
Lentivirus Infections  CCL7,NMT1,VPS28,GFAP,PLCD3,HEXIM1 10.62 2.00E-04
Inflammation CCL13,CCL7,MAP3K14,CCL11,CCL8,CCL1 9.15 3.00E-04
Sclerosis PADI3,GFAP,PADI4,PADI6 13.82 9.00E-04
Multiple Sclerosis PADI3,GFAP,PADI4,PADI6 12.06 1.30E-03
Rheumatoid Arthritis PADI3,GFAP,PADI4,PADI6 10.05 2.90E-03
Osteosarcoma CCL7,RECQL4,CCL8 15.55 3.70E-03
Werner Syndrome RECQL4, CCDC103 41.47 3.90E-03
Myoclonus GFAP, MEIS1 27.65 8.00E-03
Excessive 
Daytime 
Sleepiness
Diamond-Blackfan Anemia HOMER2, RPS17 103.05 1.60E-03
Enrichment was tested using WebGestalt66 from a list of genes in each association signal for the primary analysis for each trait, boundaries of the 
association signal are defined by 400kb windows around each SNP. Categories containing at least two different loci were included. 
Supplementary Table 6.  Disease associated gene sets enriched in candidate genes from sleep duration, insomnia symptons, and excessive daytime 
sleepiness genes loci. 
 Trait Transcription Factor
Fold 
Enrichment
Adjusted 
P-value
Genes
Sleep Duration HSF1 12.22 1.00E-02 FOXP2,MDFIC, UNC79, IL36RN
Insomnia SymptomsMIF1 (HERPUD1) 31.59 9.00E-04 CCDC103, BOP1, EFTUD2, HSF1
Excessive 
Daytime 
Sleepiness
MEF2 (V$AMEF2_Q6) 16.37 2.64E-02 JUN, PPP2R2B, FAM46A
Supplementary Table 7.  Transcription factor binding site enrichment in candidate sleep duration, insomnia symptoms, and excessive 
daytime sleepiness genes from significant loci. 
Enrichment was tested using WebGestalt66 from a list of genes in each association signal, boundaries of the association signal are 
defined by SNPs with pairwise linkage disequilibrium (r2) >= 0.20.
 
 Supplementary Table 8.  Replication in UK Biobank of genetic variants previously reported to be associated with sleep duration, insomnia symptoms, or excessive daytime. sleepiness
Trait SNP Gene
Chr:position             
NCBI 37
Alleles (E/A)
Imputation 
Quality
MAF Beta (SE) p -val
Bonferroni 
corrected  
p -val
Meta Analysis     
p-val
First author, Year PMID Original Trait
Sleep Duration
rs11932595 CLOCK 4:56323597 G/A 1.00 0.399 -0.001 (0.004) 0.822 1 0.952 Allebrandt, 2010 20149345 Sleep Duration
rs12649507 CLOCK 4:56380484 A/G 1.00 0.305 0.00 (0.005) 0.982 1 0.747 Sleep Duration
rs11046205 ABCC9 12:21992326 A/G 0.99 0.184 -0.001 (0.005) 0.801 1 0.422 Allebrandt, 2013 22105623 Sleep Duration
rs4780805 TMC5 16:19404645 G/A 0.98 0.144 0.003 (0.006) 0.591 1 0.219 Byrne, 2013 23728906 Sleep Duration
rs11214607 DRD2 11:113312139 G/T 0.97 0.159 0.013 (0.006) 0.025 0.48 8.451E-05 Cade, 2015 26464489 Sleep Duration
rs17601612 DRD2 11:113317745 C/G 0.99 0.383 -0.014 (0.004) 1.406E-03 0.027 5.435E-07 Sleep Duration
rs6599077 MYRIP 3:40096618 A/G 1.00 0.279 -0.001 (0.005) 0.809 1 - Gottlieb, 2007* 17903308 Sleep Duration
rs1823125 PAX-8 2:114090412 G/A 1.00 0.219 0.038 (0.005) 9.953E-14 1.89E-12 1.852E-22 Gottlieb, 2014 25469926 Sleep Duration
rs1191685 PAX-8 2:114094984 G/C 1.00 0.410 -0.020 (0.004) 2.508E-06 4.77E-05 4.616E-13 Sleep Duration
rs4587207 IER3/DDR1 6:30766945 G/A 1.00 0.140 -0.006 (0.006) 0.320 1 1.040E-04 Sleep Duration
rs10914351 PTPRU 1:30234031 T/G 1.00 0.021 0.029 (0.015) 0.047 1 0.012 Oillila, 2014 25109461 Sleep Duration
rs1037079 PCDH7/CENTD1 4:32590048 T/C 0.98 0.044 -0.024 (0.010) 0.021 0.40 0.079 Sleep Duration
rs2031573 KLF6 10:4001897 T/C 0.98 0.190 0.001 (0.005) 0.798 1 0.755 Sleep Duration
rs17043459 DPP10 2:115493714 A/G 0.75 0.000 0.342 (0.378) 0.365 1 0.599 Scheinfeldt, 2015 26333835 Sleep Duration
rs16900727 CDH6 5:31150659 C/A 0.27 0.000 -0.401 (0.408) 0.326 1 0.546 Sleep Duration
rs41463746 ELOVL 6:10983568 T/C 0.13 0.000 1.098 (0.989) 0.267 1 0.135 Sleep Duration
rs17122013 SORCS1 10:108820205 C/A 0.61 0.000 0.098 (0.244) 0.688 1 0.459 Sleep Duration
rs7096948 FAM204A/ PRLHR 10:120187299 G/C 0.74 0.000 0.392 (0.393) 0.318 1 0.566 Sleep Duration
rs41348446 ARNTL 11:13259561 A/G 0.56 0.000 0.036 (0.143) 0.802 1 0.562 Sleep Duration
Insomnia Symptoms OR (95%CI)
rs521704 GBP1 1:89680554 A/C 1.00 0.488 0.995 [0.973-1.018] 0.648 1 0.208 Byrne, 2012 22754043 Caffeine induced insomnia adj for IFS
rs4822498 ADORA2A 22:24876800 C/T 0.99 0.399 0.982 [0.959-1.005] 0.142 1 0.050 22754043 Caffeine induced insomnia
rs11174478 SLC2A13 12:40354244 A/G 0.98 0.390 1.001 [0.977-1.024] 0.963 1 0.330 Byrne, 2013 23728906 Insomnia Factor Score
rs7304986 CACNA1C 12:2438105 C/T 1.00 0.016 0.989 [0.902-1.084] 0.912 1 0.405 23728906 Sleep Latency
rs2302729 CACNA1C 12:2783972 C/T 0.99 0.168 1.012 [0.981-1.043] 0.484 1 0.834 23728906 Insomnia
rs1986116 WNCG 14:77513844 C/T 0.99 0.240 0.989 [0.963-1.016] 0.315 1 0.052 23728906 Sleep quality
rs1823068 PDE4D 5:58676049 G/A 0.97 0.141 1.033 [0.999-1.067] 0.057 1 - Gottlieb, 2007* 17903308 Sleepiness
rs1154155 TRA 14:23002684 G/T 1.00 0.151 1.014 [0.982-1.047] 0.399 1 0.001 Hallmayer, 2009 19412176 Narcolepsy
rs2858884 HLA-DQ2 6:32700083 C/A 1.00 0.223 1.001 [0.974-1.029] 0.936 1 0.481 Hor, 2010 20711174 Narcolepsy
rs16826005 NCKAP1 2:134266001 G/A 1.00 0.040 1.017 [0.959-1.078] 0.430 1 0.173 Peer , 2013 23646285 HLA negative essential hypersomnia
rs10988217 CRAT 9:131888116 G/A 1.00 0.394 0.998 [0.975-1.022] 0.579 1 0.811 23646285 HLA negative essential hypersomnia
rs11854769 SPRED1 15:38502243 T/C 0.99 0.250 0.987 [0.961-1.013] 0.696 1 0.880 23646285 HLA negative essential hypersomnia
Excessive Daytime Sleepiness Beta (SE)
rs1986116 WNCG 14:77513844 C/T 0.99 0.240 -0.006 (0.005) 0.247 1 0.065 Byrne, 2013 23728906 Sleep quality
rs1823068 PDE4D 5:58676049 G/A 0.97 0.141 0.007 (0.006) 0.269 1 - Gottlieb, 2007* 17903308 Sleepiness
rs1154155 TRA 14:23002684 G/T 1.00 0.150 -0.005 (0.006) 0.354 1 0.994 Hallmayer, 2009 19412176 Narcolepsy
rs2858884 HLA-DQ2 6:32700083 C/A 1.00 0.223 -0.001 (0.005) 0.790 1 0.408 Hor, 2010 20711174 Narcolepsy
rs12425451 TEAD4 12:3164923 T/C 0.95 0.277 -0.003 (0.005) 0.504 1 0.880 Luca, 2013 23496005 Age at onset of cataplexy in narcolepsy
rs16966122 THEG5 19:32158464 G/A 1.00 0.170 0.005 (0.006) 0.360 1 0.168 23496005 ESS
rs2859998 UBXN2B 8:59324162 A/G 1.00 0.299 -0.005 (0.005) 0.240 1 0.091 23496005 Age at onset of EDS in narcolepsy
rs5770917 CPT1B 22:51017353 C/T 1.00 0.048 -0.002 (0.01) 0.831 1 0.811 Miyagawa, 2008 18820697 Narcolepsy
rs11854769 SPRED1 15:38502243 T/C 0.99 0.249 0.002 (0.005) 0.649 1 0.398 Peer, 2013 23646285 HLA negative essential hypersomnia
rs10988217 CRAT 9:131888116 G/A 1.00 0.394 -0.002 (0.004) 0.653 1 0.825 23646285 HLA negative essential hypersomnia
rs16826005 NCKAP1 2:134266001 G/A 1.00 0.040 0.018 (0.011) 0.097 1 0.044 23646285 HLA negative essential hypersomnia
Sleep trait GWAS results are adjusted for age, sex, genetic ancestry, and genotyping array.  E=effect allele, A=alternative allele, MAF=minor allele frequency, SE=standard error, PMID=pubmed ID.  Bold indicates Bonferroni corrected p<0.05.  
Meta-analysis performed using a sample size weighted approach in METAL. * indicated the original effect allele was unavailable, therefore Meta analysis was not performed.
Category
Fold 
Enrichment
SE p -value
Fold 
Enrichment
SE p -value
Fold 
Enrichment
SE p -value
29 mammals conserved 14.160 4.700 5.11E-03 15.052 4.189 7.96E-04 18.037 4.975 6.15E-04
29 mammals conserved, extended 1.761 0.306 1.27E-02 2.023 0.309 9.22E-04 1.523 0.355 1.41E-01
3-PrimeUTR -2.261 3.751 3.85E-01 3.368 3.545 5.04E-01 -0.177 4.339 7.86E-01
3-PrimeUTR, extended -1.216 1.954 2.57E-01 1.643 1.645 6.96E-01 0.620 1.928 8.44E-01
5-PrimeUTR -2.651 6.903 5.97E-01 2.428 4.887 7.70E-01 9.022 7.606 2.92E-01
5-PrimeUTR, extended -0.687 1.662 3.10E-01 0.415 1.558 7.07E-01 0.578 2.141 8.44E-01
Coding 1.433 3.943 9.12E-01 1.076 3.601 9.83E-01 1.880 4.315 8.38E-01
Coding, extended -1.497 1.019 1.43E-02 0.643 0.926 7.00E-01 0.207 1.116 4.77E-01
CTCF -6.797 3.688 3.45E-02 -1.885 3.389 3.95E-01 -1.526 4.718 5.92E-01
CTCF, extended 1.011 1.274 9.93E-01 0.524 1.118 6.71E-01 1.081 1.589 9.59E-01
DGF -1.199 1.641 1.80E-01 0.357 1.290 6.18E-01 -1.509 1.890 1.84E-01
DGF, extended 1.001 0.277 9.98E-01 1.245 0.232 2.91E-01 1.607 0.328 6.44E-02
DHS 0.820 1.453 9.01E-01 1.958 1.262 4.48E-01 -2.099 1.761 7.84E-02
DHS peaks -0.619 1.769 3.60E-01 1.028 1.653 9.87E-01 -2.881 2.162 7.27E-02
DHS, extended 1.117 0.335 7.28E-01 2.053 0.315 8.39E-04 1.305 0.406 4.52E-01
Enhancer 4.409 1.644 3.81E-02 4.408 1.741 5.03E-02 1.456 2.195 8.36E-01
Enhancer, extended 2.125 0.631 7.44E-02 2.957 0.665 3.24E-03 0.328 0.936 4.73E-01
FetalDHS -2.488 2.229 1.18E-01 3.854 1.899 1.33E-01 -0.318 2.545 6.04E-01
FetalDHS, extended 1.471 0.541 3.84E-01 2.852 0.549 7.37E-04 1.666 0.699 3.41E-01
H3K27ac 1.494 0.206 1.65E-02 1.358 0.175 4.05E-02 0.880 0.232 6.04E-01
H3K27ac, extended 1.060 0.303 8.42E-01 1.658 0.305 3.08E-02 0.660 0.411 4.08E-01
H3K4me1 1.667 0.358 6.27E-02 1.995 0.395 1.18E-02 0.377 0.471 1.86E-01
H3K4me1 peaks 3.223 1.090 4.14E-02 3.626 1.004 8.94E-03 0.525 1.355 7.26E-01
H3K4me1, extended 1.243 0.150 1.06E-01 1.402 0.144 5.13E-03 1.278 0.204 1.73E-01
H3K4me3 1.058 0.756 9.39E-01 2.996 0.842 1.77E-02 2.159 1.009 2.51E-01
H3K4me3 peaks 0.498 2.641 8.49E-01 5.872 2.726 7.39E-02 4.109 3.243 3.38E-01
H3K4me3, extended 1.261 0.449 5.62E-01 1.992 0.420 1.82E-02 0.083 0.625 1.42E-01
H3K9ac 1.506 0.910 5.78E-01 3.951 0.907 1.15E-03 1.250 1.191 8.33E-01
H3K9ac peaks 0.014 2.776 7.22E-01 3.982 2.856 2.96E-01 5.782 4.013 2.33E-01
H3K9ac, extended 1.516 0.466 2.68E-01 1.947 0.409 2.05E-02 0.710 0.529 5.83E-01
Intron 1.062 0.142 6.64E-01 1.189 0.154 2.20E-01 1.109 0.184 5.53E-01
Intron, extended 1.126 0.128 3.24E-01 1.019 0.115 8.70E-01 1.273 0.161 9.02E-02
Promoter 0.197 2.121 7.05E-01 5.554 2.211 3.94E-02 3.822 2.813 3.16E-01
Promoter Flanking 3.365 6.817 7.29E-01 9.261 5.879 1.60E-01 3.390 7.954 7.64E-01
Promoter Flanking, extended 3.433 1.933 2.08E-01 3.538 1.859 1.72E-01 1.043 2.525 9.86E-01
Promoter, extended 2.388 1.298 2.85E-01 2.875 1.186 1.14E-01 1.337 1.540 8.27E-01
Repressed 0.905 0.350 7.86E-01 0.879 0.339 7.21E-01 0.442 0.507 2.71E-01
Repressed, extended 0.931 0.091 4.44E-01 0.770 0.078 3.28E-03 0.898 0.119 3.90E-01
SuperEnhancer 1.148 0.263 5.73E-01 1.780 0.274 4.38E-03 1.524 0.338 1.21E-01
SuperEnhancer, extended 1.285 0.238 2.30E-01 1.433 0.255 9.03E-02 1.582 0.335 8.20E-02
TFBS 2.492 1.864 4.24E-01 3.450 1.211 4.31E-02 0.792 1.579 8.95E-01
TFBS, extended 1.420 0.479 3.81E-01 1.898 0.422 3.33E-02 1.335 0.576 5.61E-01
Transcribed 1.101 0.423 8.12E-01 0.952 0.362 8.94E-01 1.684 0.580 2.38E-01
Transcribed, extended 0.891 0.156 4.84E-01 1.041 0.147 7.78E-01 1.007 0.158 9.64E-01
TSS -5.445 3.438 6.09E-02 4.300 3.198 3.02E-01 7.675 4.255 1.17E-01
TSS, extended 3.446 1.699 1.50E-01 5.427 1.668 7.93E-03 2.037 2.206 6.38E-01
Weak Enhancer 9.976 4.425 4.25E-02 10.814 3.747 8.81E-03 5.142 4.841 3.92E-01
Weak Enhancer, extended 3.236 1.036 3.09E-02 3.017 0.909 2.65E-02 0.898 1.300 9.37E-01
Supplementary Table 9.  Heritability of sleep duration, insomnia symptoms, and excessive daytime sleepiness partitioned across functional annotation 
class using LDSC.
Sleep Duration Insomnia Symptoms Excessive Daytime Sleepiness
Bold=significant after multiple testing correction.  SE=standard error.
Supplementary Table 10.  Conditional analysis of the MEIS1  locus association signal with insomnia symptoms.   
Chr Position hg19 OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
MEIS1 lead insomnia symptoms SNP rs113851554 2 66750564 1.26 (1.20 - 1.33) 9.10 x10-19 - - 1.23 (1.12 - 1.36) 3.01 x10-5 1.28 (1.21 - 1.35) 1.27 x10-17
MEIS1 lead RLS GWAS SNP rs2300478 2 66781453 1.04 (1.01 - 1.06) 1.04x10-2 0.98 (0.95 - 1.01) 0.24 0.99 (0.97 - 1.02) 0.71 - -
MEIS1 3'UTR RLS associated SNP rs11693221 2 66799986 1.26 (1.19 - 1.33) 5.14 x10-15 1.03 (0.93 - 1.15) 0.54 - - 1.26 (1.19 - 1.34) 1.35 x10-13
Conditioning on the lead SNP abolishes the lead regional association signal and shows no strong secondary association signals.  Analysis conditional on previously reported RLS GWAS SNP rs2300478 does not alter 
insomnia symptoms association signals.  Analysis conditional on rs11693221, a rare MEIS1 3’ UTR SNP discovered by sequence analysis and also associated with RLS, attenuates the lead association signal.  
Associations are additionally adjusted for age, sex, ancestry PCs, and genotyping array.
Baseline Adj rs113851554 Adj rs11693221 Adj rs2300478
Restless Legs 
Syndrome*
Periodic Limb 
Movements* 
SNP CHR BP Gene region
Alleles 
(E/A)
Imputation 
quality
MAF OR OR OR(95%CI) p -val
rs113851554# 2 66,750,564 MEIS1 T/G 1 0.057 4.42 n/a 1.26 (1.20 - 1.33) 9.10 x10-19
rs2300478# 2 66,781,453 MEIS1 G/T 1 0.252 1.68 1.28 1.04 (1.01 - 1.06) 1.04x10-2
rs6747972 2 68,070,225
intergenic 
(MEIS1) 
A/G 1 0.424 1.23 1.04 1.02 (1.00 - 1.05) 9.67x10-2
rs9357271 6 38,365,873 BTBD9 T/C 1 0.209 1.47 1.45 1.02 (0.99 - 1.04) 0.498
rs1975197 9 8,846,955 PTPRD A/G 0.98 0.179 1.29 1.3 1.03 (1.00 - 1.06) 8.69x10-2
rs12593813 15 68,036,852
MAP2K5/ 
LBXCOR1
G/A 0.98 0.322 1.41 1.24 1.04 (1.01 - 1.06) 4.92x10-3
rs3104767 16 52,624,738TOX3/BC034767 G/T 1 0.411 1.33 1.29 1.03 (1.01 - 1.05) 6.57x10-3
Weighted Genetic Risk Score RLS 1.06 (1.05 - 1.07) 1.17x10-21
Weighted Genetic Risk Score RLS without rs113851554 1.03 (1.02 - 1.03) 8.03x10-7
Weighted Genetic Risk Score PLM 1.02 (1.01 - 1.03) 5.99x10-6
Insomnia symptom GWAS results are adjusted for age, sex, genetic ancestry, and genotyping array.  E=effect allele, A=alternative allele, MAF=minor allele 
frequency, OR=Odds Ratio, CI=confidence interval, * single SNP effect estimates for Restless leg syndrome and periodic limb movements are from Winkelmann 
et a;, PLoS Genet 2011 and Moore et al.Sleep 2014. #these SNPs represent the same underlying MEIS1 association signal
Supplementary Table 11.  Common genetic variants for restless legs syndrome (RLS) associate with increased insomnia symptoms in the UK 
Biobank.  
Insomnia Symptoms 
(n=58,702)
 Phenotype First author, Year PMID rg p-value rg p-value rg p-value
Birth Weight Horikoshi, M. et al ., 2013 23202124 -0.270 7.51E-04 -0.114 1.20E-01 0.042 6.25E-01
Height Wood, A.R.et al. 2014 25282103 0.053 1.28E-01 -0.037 2.45E-01 0.008 7.87E-01
BMI Locke, A.E. et al., 2015 25673413 -0.092 1.51E-02 0.147 5.11E-05 0.199 3.12E-09
Waist Circumference Shungin, D. et al., 2015 25673412 -0.046 2.57E-01 0.165 2.96E-05 0.199 2.12E-07
Waist-Hip Ratio Shungin, D. et al., 2015 25673412 -0.001 9.86E-01 0.127 3.83E-03 0.101 1.09E-02
T2D Morris, A.P. et al ., 2012 22885922 0.140 3.98E-02 0.113 1.27E-01 0.049 5.01E-01
HOMA-IR Scott, R.A. et al., 2012 22885924 0.090 4.29E-01 0.354 4.42E-04 0.253 5.52E-03
Fasting Insulin Scott, R.A. et al., 2012 22885924 0.040 6.09E-01 0.367 1.85E-07 0.231 4.24E-03
Fasting Glucose Scott, R.A. et al., 2012 22885924 0.000 9.97E-01 0.237 3.35E-04 0.036 5.99E-01
Coronary Artery Disease Nikpay, M. et al. , 2015 26343387 -0.044 5.45E-01 0.168 1.30E-02 0.111 1.29E-01
Crohn's Disease Franke, A., et al., 2010 21102463 0.183 1.87E-03 -0.067 1.42E-01 0.008 8.84E-01
Rheumatoid Arthritis Stahl, E.A., et al. 2010 20453842 0.011 8.71E-01 -0.041 5.27E-01 -0.037 5.81E-01
Neck BMD Rivadeneira, F. et al , 2009 19801982 0.120 1.78E-02 -0.113 8.53E-03 0.030 5.73E-01
Schizophrenia PGC et al. 2014 25056061 0.290 1.90E-13 -0.052 2.73E-01 0.065 8.90E-02
Bipolar PGC et al. 2011 21926972 0.213 3.29E-03 -0.066 2.49E-01 0.052 4.47E-01
Depression PGC et al. 2013 22472876 0.088 3.96E-01 0.344 5.58E-04 0.130 1.59E-01
Alzheimer's Lambert, J. et al. , 2013 24162737 0.091 4.39E-01 -0.135 1.65E-01 -0.026 8.07E-01
Autism Spectrum Robinson, E.B., et al., 2016 26998691 -0.015 8.76E-01 0.056 4.77E-01 0.019 7.95E-01
Cigarettes per Day TAG consortium, et al. , 2010 20418890 -0.176 9.84E-02 0.313 3.29E-03 0.146 2.17E-01
Years of Education Rietveld, C.A. et al. , 2013 23722424 0.026 6.57E-01 -0.278 3.22E-08 -0.028 6.25E-01
Sleep Duration
Insomnia 
Symptoms
Supplementary Table 12.  Genetic correlation between sleep traits and 20 traits using LD-score regression
Excessive 
Daytime 
Sleepiness
After Bonferroni correction, p-value cut-off is 0.0025.  T2D=type 2 diabetes, BMI=body mass index, BMD=bone mineral density.
